Back to News
Market Impact: 0.2
Verastem Consensus Price Target Increased by 17.42% to $17.57
Source: Nasdaq
Analyst EstimatesAnalyst InsightsHealthcare & Biotech
The average one-year analyst price target for Verastem was revised up 17.42% to $17.57 per share from $14.96, the estimate dated September 29, 2026. The figures are aggregate analyst targets compiled by Fintel; the article provides no further context on the revision.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.25
Ticker Sentiment
VSTM0.35
More News
- The real test for Moderna’s cancer vaccine isn’t about beating Keytruda. It’s keeping cancer from coming back in the long term.
- Oncologists Cheer Melanoma Data
- SpaceX bear flips to big bull because of AI business. Analyst now sees 70% gain
- Vertex reports positive IgAN trial data, FDA decision due Nov. 30
- Williams Trading cuts Deckers Outdoor stock price target on weak DTC trends
- Investing.com’s stocks of the week